{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:57:25Z","timestamp":1792439845803,"version":"4.5.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hepatitis B virus (HBV)-related liver cirrhosis (HBV-LC) is a significant global health issue, affecting gut microbiota (GM) composition and metabolic processes. This study aimed to explore the associations between intestinal microbiota, metabolic profiles, and disease progression in patients with HBV-LC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Fecal samples were collected prospectively from 40 healthy controls (HC) and 83 HBV-LC patients between December 2022 and August 2023. Gut microbiota alterations at various stages of liver function were analyzed using 16S rRNA gene sequencing. Untargeted metabolomics was employed to identify potential biomarkers and metabolic pathways associated with early cirrhosis. Additionally, correlations between bacterial genera, inflammatory markers, and metabolites were investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>HBV-LC patients demonstrated a significant reduction in bacterial diversity and relative abundance compared to the HC group. Genera such as <jats:italic>Alistipes<\/jats:italic> and <jats:italic>Lachnospira<\/jats:italic> were notably depleted, while <jats:italic>Fusobacterium<\/jats:italic> and <jats:italic>Enterococcus<\/jats:italic> were enriched in patients with Model for End-Stage Liver Disease (MELD) scores \u2265 21 or Child-Turcotte-Pugh C grade. Correlation analyses revealed strong associations between intestinal flora, clinical indicators of disease severity, and inflammatory factors. Metabolic analysis showed decreased levels of tocopherol and 21-hydroxypregnenolone, which were strongly linked to the reduced abundance of <jats:italic>Alistipes<\/jats:italic> and <jats:italic>Lachnospira<\/jats:italic>. Biosynthesis of unsaturated fatty acids and linoleic acid metabolism emerged as critical enrichment pathways.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>HBV-LC patients displayed significant alterations in gut microbiota and fecal metabolites, which correlated closely with disease severity and inflammatory status. These findings provide new insights into cirrhosis pathogenesis and suggest potential biomarkers for early diagnosis and disease monitoring.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2025.1560564","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T05:14:48Z","timestamp":1747631688000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Distinct gut microbiota and metabolomic profiles in HBV-related liver cirrhosis: insights into disease progression"],"prefix":"10.3389","volume":"15","author":[{"given":"Ke","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cgh.2018.08.008","article-title":"Altered microbiome in patients with cirrhosis and complications","volume":"17","author":"Acharya","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41564-022-01273-y","article-title":"Longitudinal multi-omics analyses of the gut-liver axis reveals metabolic dysregulation in hepatitis C infection and cirrhosis","volume":"8","author":"Ali","year":"2023","journal-title":"Nat. Microbiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1006\/jsre.2000.5825","article-title":"Regenerative capacities of normal and cirrhotic livers following 70% hepatectomy in rats and the effect of alpha-tocopherol on cirrhotic regeneration","volume":"89","author":"Andiran","year":"2000","journal-title":"J. Surg. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/liv.13986","article-title":"Potential mechanisms linking gut microbiota and portal hypertension","volume":"39","author":"Baffy","year":"2019","journal-title":"Liver Int."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2018.00420","article-title":"Ascitic bacterial composition is associated with clinical outcomes in cirrhotic patients with culture-negative and non-neutrocytic ascites","volume":"8","author":"Chen","year":"2018","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1053\/j.gastro.2020.04.077","article-title":"Contribution of the intestinal microbiome and gut barrier to hepatic disorders","volume":"159","author":"Chopyk","year":"2020","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jhep.2021.06.043","article-title":"Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis","volume":"75","author":"Cl\u00e0ria","year":"2021","journal-title":"J. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11739-023-03374-w","article-title":"Gut microbiota, intestinal permeability, and systemic inflammation: A narrative review","volume":"19","author":"Di Vincenzo","year":"2024","journal-title":"Intern. Emerg. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis","volume":"398","author":"Gin\u00e8s","year":"2021","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: Current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis\u2014aetiology, trends and predictions","volume":"20","author":"Huang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/hepr.14016","article-title":"Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside\/nucleotide analog therapy","volume":"54","author":"Kozuka","year":"2024","journal-title":"Hepatol. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/s12876-024-03494-3","article-title":"Risk factors and prognostic impact of new decompensated events in hospitalized patients with decompensated cirrhosis","volume":"24","author":"Lan","year":"2024","journal-title":"BMC Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.addr.2020.06.028","article-title":"Bioactive lipids, inflammation and chronic diseases","volume":"159","author":"Leuti","year":"2020","journal-title":"Adv. Drug Delivery Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41575-022-00724-5","article-title":"The scientific basis of combination therapy for chronic hepatitis B functional cure","volume":"20","author":"Lim","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1016\/j.cmet.2024.09.007","article-title":"Sensing steroid hormone 17\u03b1-hydroxypregnenolone by GPR56 enables protection from ferroptosis-induced liver injury","volume":"36","author":"Lin","year":"2024","journal-title":"Cell Metab."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1140126","article-title":"Intestinal flora plays a role in the progression of hepatitis-cirrhosis-liver cancer","volume":"13","author":"Liu","year":"2023","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.aohep.2019.06.020","article-title":"Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis","volume":"18","author":"Liu","year":"2019","journal-title":"Ann. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.jhep.2020.03.046","article-title":"Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis","volume":"73","author":"L\u00f3pez-Vicario","year":"2020","journal-title":"J. Hepatol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/nu16203494","article-title":"Intestinal barrier impairment, preservation, and repair: An update","volume":"16","author":"Matar","year":"2024","journal-title":"Nutrients"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00906","article-title":"The genus Alistipes: Gut bacteria with emerging implications to inflammation, cancer, and mental health","volume":"11","author":"Parker","year":"2020","journal-title":"Front. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2022.2155018","article-title":"Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response","volume":"15","author":"Shen","year":"2023","journal-title":"Gut Microbes"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2022.100676","article-title":"Gut microbiota dysbiosis in patients with hepatitis B virus-related cirrhosis","volume":"27","author":"Shu","year":"2022","journal-title":"Ann. Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41575-020-00376-3","article-title":"Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure","volume":"18","author":"Trebicka","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.jhep.2020.11.013","article-title":"The microbiota in cirrhosis and its role in hepatic decompensation","volume":"75","author":"Trebicka","year":"2021","journal-title":"J. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1053\/j.gastro.2024.05.014","article-title":"Gut microbiota-derived butyrate induces epigenetic and metabolic reprogramming in myeloid-derived suppressor cells to alleviate primary biliary cholangitis","volume":"167","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"7088","DOI":"10.3748\/wjg.v26.i45.7088","article-title":"Chinese guidelines on the management of liver cirrhosis (abbreviated version)","volume":"26","author":"Xu","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012661","article-title":"Role of intestinal microbes in chronic liver diseases","volume":"23","author":"Xu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112806","article-title":"Bile acid receptors and the gut-liver axis in nonalcoholic fatty liver disease","volume":"10","author":"Xue","year":"2021","journal-title":"Cells"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112895","article-title":"DHA-enriched phosphatidylserine ameliorates cyclophosphamide-induced liver injury via regulating the gut-liver axis","volume":"140","author":"Zhang","year":"2024","journal-title":"Int. Immunopharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20222524","article-title":"The pathogenesis of gut microbiota in hepatic encephalopathy by the gut-liver-brain axis","volume":"43","author":"Zhu","year":"2023","journal-title":"Biosci. Rep."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1560564\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T05:14:49Z","timestamp":1747631689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1560564\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":32,"alternative-id":["10.3389\/fcimb.2025.1560564"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1560564","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"article-number":"1560564"}}